At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 140 enrolled
Drug / intervention
Placebo +4 moredrug
Likely dose
Placebo 0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Confirm Dose Responsiveness Following 12 Weeks of the Administration of CP-690,550 (4 Doses) or Placebo in Subjects With Active Rheumatoid Arthritis Inadequately Controlled With Methotrexate Alone
In Brief
A Phase 2 clinical trial evaluating Placebo and CP-690,550 for Arthritis, Rheumatoid. Completed, enrolled 140 participants across 18 sites.
Detailed Summary
The purpose of this study is to determine the effectiveness and safety, over 3 months, of 4 dose regimens of CP-690,550, combined with methotrexate, for the treatment with active rheumatoid arthritis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArthritis, Rheumatoid
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2008
First PostedJan 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedJan 29, 2008
Enrollment StartJan 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 18.4 years ago
Interventions
Placebodrug
0 mg BID, 3 blinded tablets administered BID for 12 weeks
CP-690,550drug
10 mg BID, 3 blinded tablets administered BID for 12 weeks
CP-690,550drug
1 mg BID, 3 blinded tablets administered BID for 12 weeks
CP-690,550drug
3 mg BID, 3 blinded tablets administered BID for 12 weeks
CP-690,550drug
5 mg BID, 3 blinded tablets administered BID for 12 weeks